Medtronic to Acquire Contego Medical for $380M
The deal would give Medtronic full ownership of Contego's carotid and thrombectomy device lines, which it currently distributes in the US.
Updated on Nov. 16, 2026 in Stroke

Live Poll
Do you trust big medical companies to put patients ahead of profits?
Medtronic plc announced its intent to acquire Contego Medical, a privately held medical device company focused on carotid artery disease and peripheral thrombectomy, in a deal valued at $380 million plus potential post-acquisition payments. The transaction still awaits customary closing conditions.
Why it matters
The acquisition converts an exclusive US distribution agreement first announced in January 2025 into full ownership of Contego's FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices. Carotid artery plaque rupture or embolization accounts for about 20% of ischemic strokes, placing the technology in a significant area of stroke care.
The PERFORMANCE III study reported zero strokes, zero neurological deaths, zero cranial nerve injuries and zero myocardial infarctions at 30 days for the Neuroguard IEP Direct System. The study's sample size and follow-up beyond 30 days are not stated in the source.
The players
Medtronic plc
Medtronic is a global medical technology company headquartered in Galway, Ireland, with more than 90,000 employees across over 150 countries.
Contego Medical
Contego Medical is a privately held medical device company developing carotid artery and peripheral thrombectomy technologies, backed by investors including Hatteras Venture Partners and Lightstone Ventures.
The details
Medtronic announced its intent to acquire Contego Medical on November 16, 2026, with the deal valued at $380 million and potential payments after acquisition. Contego's investors include Hatteras Venture Partners, U.S. Venture Partners, Lightstone Ventures and Amzak Health.
Timeline
January 2025: Exclusive US distribution agreement with Contego first announced.
November 16, 2026: Medtronic announces intent to acquire Contego Medical.
November 24, 2026: Medtronic reports quarterly results and may update on the acquisition.
Third quarter of Medtronic's fiscal year: expected closing of the acquisition.
Roadmap
The deal extends Medtronic's stroke-related portfolio into carotid artery disease, an area where plaque rupture or embolization drives about 20% of ischemic strokes. It converts a distribution relationship into direct ownership of the FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices.
For patients facing carotid artery disease or stroke risk from plaque rupture, the acquisition could change which devices are available through Medtronic's channels once the deal closes. The source does not indicate any change to current prescribing, insurance coverage or procedure access.
The takeaway
Patients and clinicians tracking stroke treatment options should watch whether the Neuroguard IEP Direct System's 30-day safety profile is supported by further data after the deal closes. Medtronic's ownership may affect availability and pricing once the transaction is complete.
What happens next
Medtronic is expected to close the Contego Medical acquisition in the third quarter of its fiscal year, and it may update on the deal when it reports quarterly results on November 24, 2026.
Further reading
For more on how carotid and thrombectomy devices fit into stroke treatment, see the Stroke section.
Live Poll
Do you trust big medical companies to put patients ahead of profits?



